Nerve damage drug study for MGUS patients withdrawn before starting
NCT ID NCT06046287
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 25 times
Summary
This study was designed to see if the drug daratumumab could help people with a blood condition called MGUS who also have nerve damage (peripheral neuropathy). Participants would have received weekly injections for two months, then every other week for four more months. However, the study was withdrawn before enrolling anyone, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
-
Lombardi Comprehensive Cancer Center, Georgetown University
Washington D.C., District of Columbia, 20007, United States
Conditions
Explore the condition pages connected to this study.